Tofacitinib, a prescribed Janus kinase (JAK) inhibitor, operates as a disease-modifying anti-rheumatic drug (DMARD). Its mechanism involves the suppression of the immune system. Available in various forms such as tablets (Xeljanz), extended-release tablets (Xeljanz XR), and oral solutions. At the heart of Gempharr Healthcare’s groundbreaking pharmaceutical innovation lies the potent.
